Home » Cancer Treatment

GS45 targets ovarian cancer cells while leaving healthy cells intact

19 April 2010 Email This Post Email This Post Print This Post Print This Post

Ovarian Cancer RibbonGS45, an antibody-like molecule able to target tumor cells in ovarian cancer patients while leaving healthy cells intact, was recently isolated by Gregory Adams, Ph.D., co-leader of the Developmental Therapeutics Program at Fox Chase Cancer Center, and colleagues.

The GS45 molecule targets a receptor called the Müllerian Inhibiting Substance Type II Receptor (MISIIR), which is scarce in normal tissue, but more abundantly present on the surface of human ovarian cancer cells.

“A general problem with targeted therapies is that many of the targets found on cancer cells are also found on normal cells,” says Karakasheva. “When you direct cell-killing drugs at those targets, you get side effects. The great thing about our target is that in healthy tissue, it’s primarily restricted to the reproductive system, and its expression dramatically increases in ovarian cancer.” “But attractive as MISIIR is as a target, finding antibodies that will home in and bind to it has been a challenge,” Adams says.

Using a method called combinatorial single-chain Fv phage display, in which human antibody fragments are expressed and selected on the surface of viruses that infect bacteria, Karakasheva and Adams managed to isolate a group of good candidates, including GS45.

They have just completed engineering the fragments into full-size human antibodies that will be used in experiments with a mouse model of human ovarian cancer. The first step will be to demonstrate that GS45 actually does target only ovarian cancer cells, not healthy tissue. Then, the researchers plan to attach a cell-killing drug to the antibody, to explore its potential in cancer treatment.

“Because mouse and human MISIIR are almost identical, whatever the mouse experiments reveal about targeting and toxicity is likely to apply to humans,” Adams says. “This puts us in a powerful position to move this work forward through pre-clinical studies to a point where we’ll know if it’s worth taking to clinical trials.”

Source: EurekAlert!

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Leave your response!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.